BML-210 [CAS 537034-17-6]

BML-210 is a potent HDAC inhibitor. BML-210 can inhibit the HDAC4-VP16-driven reporter signal with an apparent IC50 of ∼5 µM. BML-210 has a specific disruptive effect on the HDAC4:MEF2 interaction. BML-210 causes an increase in the G0/G1 phase. BML-210 induces apoptosis and displays antitumour activities in orthotopic mammary tumours in mice[1][2][3].

[537034-17-6]

C20H25N3O2

339.43

O=C(NC1=CC=CC=C1N)CCCCCCC(NC2=CC=CC=C2)=O

Apoptosis; HDAC

HDAC4

10mM

98.04

DMSO : ≥ 30 mg/mL

-20°C, 3 years; 4°C, 2 years (Powder)

Room Temperature

H302, H361, H372, H410

H302, H361, H372, H410